Synthesis, radiolabeling, and in vivo pharmacokinetic evaluation of the amyloid beta radioligand [11C]AZD4694 in nonhuman primates.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: Springer Country of Publication: United States NLM ID: 101125610 Publication Model: Print Cited Medium: Internet ISSN: 1860-2002 (Electronic) Linking ISSN: 15361632 NLM ISO Abbreviation: Mol Imaging Biol Subsets: MEDLINE
    • Publication Information:
      Publication: 2005- : New York, NY : Springer
      Original Publication: New York, NY : Elsevier Science, c2001-
    • Subject Terms:
    • Abstract:
      Purpose: [(18)F]AZD4694 (2-(2-(18)F-fluoro-6-(methylamino)-3-pyridyl)benzofuran-5-ol) is a radioligand suitable for imaging of amyloid beta deposits in the living human brain using positron emission tomography (PET). Here, we report the preparation and pharmacokinetic profile of its carbon-11 (t1/2 = 20.4 min) labeled isotopolog [(11)C]AZD4694 and compare [(11)C]AZD4694 with the hitherto most widely applied amyloid PET radioligand [(11)C]Pittsburgh Compound B (PiB).
      Procedures: The immediate unlabeled precursor to [(11)C]AZD4694 was prepared in a four-step convergent synthesis. Subsequent N-(11)C-methylation of this precursor with [(11)C]methyl iodide yielded [(11)C]AZD4694, which after isolation and formulation was injected into cynomolgus monkeys. The radioactivity in nonhuman primate brain following injection of [(11)C]AZD4694 and [(11)C]PiB was measured using PET.
      Results: [(11)C]AZD4694 was prepared in a 60 % incorporation yield. In a head to head comparison with [(11)C]PiB, it appeared that [(11)C]AZD4694 displayed slightly lower nonspecific binding in white matter than [(11)C]PiB as well as more rapid pharmacokinetics in the brain.
      Conclusions: The advantageous pharmacokinetic profile and low nonspecific binding render [(11)C]AZD4694 a promising PET radioligand for imaging of amyloid beta in the human brain with PET.
    • References:
      Lancet Neurol. 2008 Feb;7(2):129-35. (PMID: 18191617)
      Am J Geriatr Psychiatry. 2002 Jan-Feb;10(1):24-35. (PMID: 11790632)
      J Nucl Med. 2009 Nov;50(11):1887-94. (PMID: 19837759)
      J Nucl Med. 2009 Aug;50(8):1251-9. (PMID: 19617318)
      Nucl Med Biol. 2002 Aug;29(6):633-42. (PMID: 12234587)
      Eur J Nucl Med Mol Imaging. 2009 Nov;36(11):1859-63. (PMID: 19495746)
      J Neurochem. 2010 Aug;114(3):784-94. (PMID: 20477945)
      J Nucl Med. 2006 Mar;47(3):520-7. (PMID: 16513622)
      Bioorg Med Chem Lett. 2010 Oct 15;20(20):6141-4. (PMID: 20817524)
      Nucl Med Biol. 1998 Apr;25(3):215-23. (PMID: 9620626)
      Ann N Y Acad Sci. 1997 Sep 26;826:242-7. (PMID: 9329695)
      Bioorg Med Chem Lett. 2012 Jul 1;22(13):4332-7. (PMID: 22647721)
      Appl Radiat Isot. 2009 Jan;67(1):106-10. (PMID: 19013077)
      J Neurochem. 2009 Mar;108(5):1177-86. (PMID: 19141073)
      J Med Chem. 2003 Jun 19;46(13):2740-54. (PMID: 12801237)
      Bioorg Med Chem Lett. 2010 Mar 15;20(6):1976-80. (PMID: 20153963)
      Synapse. 2010 Oct;64(10):733-41. (PMID: 20698029)
      J Nucl Med. 2012 Mar;53(3):415-24. (PMID: 22323782)
      Nucl Med Biol. 1996 Jul;23(5):627-34. (PMID: 8905828)
      J Nucl Med. 2002 Mar;43(3):292-303. (PMID: 11884487)
      J Cereb Blood Flow Metab. 2007 Sep;27(9):1533-9. (PMID: 17519979)
      Ann Neurol. 2004 Mar;55(3):306-19. (PMID: 14991808)
    • Accession Number:
      0 (2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole)
      0 (AZD4694)
      0 (Amyloid beta-Peptides)
      0 (Aniline Compounds)
      0 (Benzofurans)
      0 (Carbon Radioisotopes)
      0 (Hydrocarbons, Fluorinated)
      0 (Radiopharmaceuticals)
      0 (Thiazoles)
    • Publication Date:
      Date Created: 20130905 Date Completed: 20141112 Latest Revision: 20211021
    • Publication Date:
      20221213
    • Accession Number:
      10.1007/s11307-013-0666-3
    • Accession Number:
      24002613